周日报道，Lyell报告称，Ronde-Cel在2025年ASH上在LBCD中表现出高持久的完全反应，在3L+环境中，有93%的ORR和76%的CR

2025-12-08 16:21

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting
83% overall response and 61% complete response rates in cohort comprised predominantly of patients with primary refractory large B-cell lymphoma in the 2L setting
Manageable safety profile appropriate for outpatient administration; no high-grade CRS and ≤ 5% of patients with Grade ≥ 3 ICANS following dexamethasone prophylaxis
Lyell management will host an investor webcast with presenting author and ronde-cel investigator Sarah M. Larson, MD, Associate Professor at the David Geffen School of Medicine, University of California, Los Angeles, at 8:30 AM ET on Monday, December 8th